CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Financial Statements and Exhibits

CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

Story continues below

(d) Exhibits




99.1 Press Release dated April12, 2018.

EX-99.1 2 d570062dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B Initiation of Phase 2b Trial on Track for Q3 2018 SOUTH SAN FRANCISCO,…
To view the full exhibit click here


Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

An ad to help with our costs